Page last updated: 2024-11-10

16,16-dimethylprostaglandin e2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

16,16-Dimethylprostaglandin E2: A synthetic prostaglandin E analog that protects the gastric mucosa, prevents ulceration, and promotes the healing of peptic ulcers. The protective effect is independent of acid inhibition. It is also a potent inhibitor of pancreatic function and growth of experimental tumors. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

16,16-dimethylprostaglandin E2 : A prostanoid that is prostaglandin E2 in which both of the hydrogens at position 16 have been replaced by methyl groups. A synthetic analogue of prostaglandin E2, it is a potent inhibitor of pancreatic function and growth of experimental tumors. It also protects the gastric mucosa, prevents ulceration, and promotes the healing of peptic ulcers. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5283066
CHEMBL ID1221529
CHEBI ID141046
SCHEMBL ID674246
MeSH IDM0023176

Synonyms (60)

Synonym
39746-25-3
16,16-dimethyl prostaglandin e2
CHEMBL1221529
16,16-dimethylrostaglandin e2
gtpl1926
(5z,11-alpha,13e,15r)-11,15-dihydroxy-16,16-dimethyl-9-oxoprosta-5,13-dien-1-oic acid
16,16-dimethylprostaglandin e2
5-heptenoic acid, 7-(2-(4,4-dimethyl-3-hydroxy-1-octenyl)-3-hydroxy-5-oxocyclopentyl)-
brn 2896843
7-(2-(4,4-dimethyl-3-hydroxy-1-octenyl)-3-hydroxy-5-oxocyclopentyl)-5-heptenoic acid
prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-16,16-dimethyl-9-oxo-, (5z,11-alpha,13e,15r)-
LMFA03010065
16,16-dimethyl-prostaglandin e2
9-oxo-11r,15r-dihydroxy-16,16-dimethyl-5z,13e-prostadienoic acid
16,16-dimethyl-pge2
IDI1_033835
16,16-dimethyl pge2
dm-pge2
dipge2
ft-1050
NCGC00161290-02
NCGC00161290-01
c22h36o5
BSPBIO_001365
NCGC00161290-03
HMS1989E07
BML1-G03
HMS1791E07
HMS1361E07
dmpge(2)
dmpge2
(5z,11alpha,13e,15r)-11,15-dihydroxy-16,16-dimethyl-9-oxoprosta-5,13-dien-1-oic acid
CHEBI:141046
(z)-7-[(1r,2r,3r)-3-hydroxy-2-[(e,3r)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid
prosta-5,13-dien-1-oicacid, 11,15-dihydroxy-16,16-dimethyl-9-oxo-, (5z,11a,13e,15r)-
unii-m790v82vac
m790v82vac ,
ft1050
prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-16,16-dimethyl-9-oxo-, (5z,11.alpha.,13e,15r)
(5z,11.alpha.,13e,15r)-11,15-dihydroxy-16,16-dimethyl-9- oxoprosta-5,13-dien-1-oic acid
BRD-K92301463-001-01-4
SCHEMBL674246
(5z,11?,13e,15r)-11,15-dihydroxy-16,16-dimethyl-9-oxo-prosta-5,13-dien-1oic acid
9-oxo-11.alpha.,15r-dihydroxy-16,16-dimethyl-prosta-5z,13e-dien-1-oic acid
(5z,11alpha,13e,15r)-11,15-dihydroxy-16, 16-dimethyl-9-oxo-prosta-5,13-dien-1oic acid
AKOS024457938
HMS3648J05
HMS3402E07
HY-106420
Q27070785
SR-01000946434-1
sr-01000946434
BRD-K92301463-001-05-5
16,16-dimethylprostaglandin-e2
BD177551
CS-0025771
15r-dihydroxy-16,16-dimethyl-prosta-5z,13e-dien-1-oic acid
DTXSID201025748
PD021128
AT35121

Research Excerpts

Toxicity

ExcerptReferenceRelevance
", 30 min before, and every 6 hr after, the administration of bromobenzene) did not modify the disappearance curves of unchanged bromobenzene from plasma and liver, and did not modify the amount of bromobenzene metabolites covalently bound to hepatic proteins 1-24 hr after the administration of a toxic dose of bromobenzene (0."( Protective effect of 16,16-dimethyl prostaglandin E2 on the hepatotoxicity of bromobenzene in mice.
Babany, G; Degott, C; Funck-Brentano, C; Letteron, P; Pessayre, D; Tinel, M, 1984
)
0.27

Bioavailability

ExcerptReferenceRelevance
"Pharmacokinetic studies performed in toxicological studies indicate that CsA is well absorbed in rats and dogs with absolute bioavailability in the range of 10% to 30% when administered by gavage (olive oil)."( Pharmacokinetics of cyclosporine in toxicological studies.
Donatsch, P; Ryffel, B, 1986
)
0.27

Dosage Studied

ExcerptRelevanceReference
" The most effective inhibitory dosage with maximal carbachol (10(-5) M; 30."( Prostaglandin E analogue inhibition of pancreatic enzyme secretion.
Adrian, TE; Bilchik, AJ; Modlin, IM; Zucker, KA, 1989
)
0.28
" Such animals are then labeled with 51Cr-red blood cells from donor animals and dosed with the compound under evaluation."( Assessment of gastric bleeding in rats: effects of cyclooxygenase inhibitors and 16,16-dimethyl prostaglandin E2 on gastric bleeding.
Argenbright, LW; Bailey, P; Bonney, RJ; Glinka, S; Hopple, S; Humes, JL, 1987
)
0.27
" The dose-response relationship in preventing gastric mucosal damage and in inhibiting gastric acid and pepsin secretion was investigated."( Protective and antisecretory effects of the new PGE2 analogue, FCE 20700, and of 16,16 dimethyl PGE2 in pylorus-ligated rat.
Barocelli, E; Chiavarini, M; Impicciatore, M; Morini, G, 1988
)
0.27
" Dose-response studies established that optimal protection was achieved by the twice daily administration of 16,16-dimethyl prostaglandin E2 at 100 micrograms per kg (subcutaneous) or 250 micrograms per kg (oral)."( 16,16-Dimethyl prostaglandin E2 delays collagen formation in nutritional injury in rat liver.
Appelman, HD; Henley, KS; Peters, KM; Rush, BD; Ruwart, MJ; Snyder, KF,
)
0.13
" Dose-response curves for PTH- and PG-induced inhibition of 45Ca uptake into femur at 15 min were essentially parallel and indicated that the lowest doses of PTH and PG used (0."( Evidence for a novel inhibition of calcium uptake into chick bone in response to bovine parathyroid hormone (1-34) or 16, 16-dimethyl prostaglandin E2 in vivo.
Dacke, CG; Shaw, AJ, 1985
)
0.27
"The effects of intravenous infusions of the stable prostaglandin analogue 9-deoxo-16,16-dimethyl-9-methylene-PGE2 (9-methylene-PGE2) in a dosage of 10 or 24 micrograms/min were studied in the consicious euhydrated, dehydrated, and hyperhydrated with the simultaneous administration of exogenous arginine vasopressin (AVP), sheep."( The prostaglandin-analogue-9-deoxo-16,16-dimethyl-9-methylene-PGE2 inhibits the antidiuretic effect of vasopressin (AVP) in the conscious sheep.
Bygdeman, M; Christensen, NJ; GreƩn, K; Jonasson, H; Leksell, LG; Rundgren, M; Vesterqvist, O; Wallin, CJ, 1984
)
0.27
"5 ml/min) in the dosage of 20 micrograms/min for 2 h in conscious euhydrated man."( Water diuretic effect of intravenously administered 9-deoxo-16, 16-dimethyl-9-methylene-PGE2 in conscious man.
Christensen, NJ; Leksell, LG; Vesterqvist, O; Wallin, CJ, 1984
)
0.27
" Thus, the effect of prostaglandins on GE and SIT depends upon the dosage and route of administration as well as type of prostaglandin used."( The effects of PGF2 alpha, PGE2 and 16, 16 dimethyl PGE2 on gastric emptying and small intestinal transit in rat.
Rush, BD; Ruwart, MJ, 1984
)
0.27
" A dose-response study showed that the threshold ulcerogenic dose of mepirizole (30 mg/kg) did not significantly reduce alkaline secretion, whereas higher doses did."( Decrease in alkaline secretion during duodenal ulceration induced by mepirizole in rats.
Chen, MH; Jacobson, ED; Joffe, SN; Murphy, RF; Tabata, K, 1984
)
0.27
"A comparative study was conducted to assess the relative efficacy and side effects of 2 dosage schedules using 9-deoxo-16,16-dimethyl-9-methylene PGE2alpha (prostaglandin) for 2nd-trimester abortion."( The vaginal administration of 9-deoxo-16,16-dimethyl-9-methylene PGE2 for second trimester abortion.
Ballard, CA, 1981
)
0.26
" Rats were injected with indomethacin to reduce endogenous prostaglandin synthesis and dosed with prostaglandin analogues or prostacyclin."( Absorption, retention and urinary excretion of chromium-51 in rats pretreated with indomethacin and dosed with dimethylprostaglandin E2, misoprostol or prostacyclin.
Adeleye, BO; Davis-Whitenack, ML; Kamath, SM; Sangiah, S; Smith, MM; Stoecker, BJ, 1997
)
0.3
" Time course and dose-response experiments demonstrated that increased apoptosis paralleled the growth-inhibitory effects of the sulfide and sulfone."( Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
Ahnen, DJ; Finn, TS; Fryer, BH; Li, H; Pamukcu, R; Piazza, GA; Rahm, AK; Stoumen, AL, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
radiation protective agentAny compound that is able to protect normal cells from the damage caused by radiation therapy.
anti-ulcer drugOne of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.
gastrointestinal drugA drug used for its effects on the gastrointestinal system, e.g. controlling gastric acidity, regulating gastrointestinal motility and water flow, and improving digestion.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
prostanoidThe family of natural prostaglandins and prostaglandin-like compounds including prostacyclins and thromboxanes.
monocarboxylic acidAn oxoacid containing a single carboxy group.
secondary allylic alcoholAn allylic alcohol in which the carbon atom that links the double bond to the hydroxy group is also attached to one other carbon and one hydrogen.
cyclopentanonesAny alicyclic ketone that consists of a cyclopentane skeleton substituted by at least one oxo group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency70.79460.354828.065989.1251AID504847
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1131074Spasmogenic activity in nulliparous guinea pig uterine relative to PGE21979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues.
AID1131079Induction of diarrheal activity in conscious mouse at 0.1 to 3 mg/kg, iv administered for 30 mins relative to PGE21979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues.
AID1131075Bronchodilator activity in Reed-Willet guinea pig assessed as inhibition of histamine-induced bronchoconstriction at 0.28 mM administered through nebulizer for 1 min relative to PGE21979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues.
AID500948Induction of COX2-mediated AE beta-casein/TCF signaling in human K562 cells harboring AML1-ETO protein at 75 uM by luciferase reporter assay relative to control2009Nature chemical biology, Apr, Volume: 5, Issue:4
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation.
AID1131076Hypotensive activity in iv dosed PGE2-treated Mongrel dog assessed as change in blood pressure of greater than 10 mm by mercury manometer relative to PGE21979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues.
AID1131078Antisecretory activity in rat assessed as inhibition of pentagastrin-stimulated gastric acid secretion at 10 ug/kg, iv relative to PGE21979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues.
AID1346336Mouse EP3 receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
AID1346307Mouse EP4 receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
AID1346303Mouse EP2 receptor (Prostanoid receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:2
Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (523)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990329 (62.91)18.7374
1990's143 (27.34)18.2507
2000's32 (6.12)29.6817
2010's15 (2.87)24.3611
2020's4 (0.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 7.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index7.79 (24.57)
Research Supply Index6.34 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (7.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials22 (4.06%)5.53%
Reviews2 (0.37%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other518 (95.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]